Status: Recruiting
A Study on TLC590 for Managing Postsurgical Pain
This Phase 2 open-label trial investigates the pharmacokinetics (PK), pharmacodynamics, and safety profile of TLC590 across various surgical procedures. Researchers aim to determine the maximum tolerated dose (MTD) of TLC590 via Safety Monitoring Committee (SMC). The study evaluates TLC590 in bunionectomy, laparoscopy-assisted open ventral hernia repair, breast augmentation, abdominoplasty, and total knee arthroplasty models. Additionally, it determines the relative bioavailability of TLC590 to ropivacaine injection.
Participants needed: 120
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: TLC Biopharmaceuticals, Inc.Updated: Dec 2, 2025Locations: 2
Eligibility criteria
Able and willing to provide written informed consent [+13]
A clinically significant abnormal clinical laboratory test value [+19]